S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
NASDAQ:IPHA

Innate Pharma (IPHA) Stock Price, News & Analysis

$2.59
+0.17 (+7.02%)
(As of 04/16/2024 ET)
Today's Range
$2.34
$2.59
50-Day Range
$2.37
$2.88
52-Week Range
$1.81
$3.57
Volume
6,489 shs
Average Volume
11,203 shs
Market Capitalization
$209.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.75

Innate Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
276.4% Upside
$9.75 Price Target
Short Interest
Healthy
0.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Innate Pharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.94) to ($0.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.43 out of 5 stars

Medical Sector

502nd out of 930 stocks

Biological Products, Except Diagnostic Industry

82nd out of 150 stocks

IPHA stock logo

About Innate Pharma Stock (NASDAQ:IPHA)

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

IPHA Stock Price History

IPHA Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
See More Headlines
Receive IPHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IPHA
Fax
N/A
Employees
191
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.75
High Stock Price Target
$11.50
Low Stock Price Target
$8.00
Potential Upside/Downside
+276.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$66.71 million
Book Value
$0.69 per share

Miscellaneous

Free Float
55,074,000
Market Cap
$209.43 million
Optionable
Not Optionable
Beta
0.30
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Herve Brailly Ph.D. (Age 63)
    Co-Founder, Interim CEO & Chairman of Executive Board
  • Mr. Yannis Morel Ph.D. (Age 51)
    Executive VP, COO & Member of Executive Board
    Comp: $404.88k
  • Dr. François Romagné Ph.D. (Age 60)
    Founder
  • Mr. Eric Vivier D.V.M. (Age 60)
    M.B.A., Ph.D., Founder, Senior VP & Chief Scientific Officer
  • Dr. Marc Bonneville Ph.D. (Age 64)
    Founder
  • Mr. Jean Jacques Fournié Ph.D.
    Founder
  • Mr. Alessandro Moretta M.D.
    Ph.D., Founder
  • Mr. Frederic Lombard M.B.A. (Age 49)
    Senior VP & CFO
  • Dr. Sonia Quaratino M.D. (Age 62)
    Ph.D., Executive VP, Chief Medical Officer & Member of Executive Board
  • Mr. Arvind Sood
    Executive VP, President of US Operations & Member of Executive Board

IPHA Stock Analysis - Frequently Asked Questions

Should I buy or sell Innate Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPHA shares.
View IPHA analyst ratings
or view top-rated stocks.

What is Innate Pharma's stock price target for 2024?

1 equities research analysts have issued 1 year price objectives for Innate Pharma's stock. Their IPHA share price targets range from $8.00 to $11.50. On average, they predict the company's share price to reach $9.75 in the next twelve months. This suggests a possible upside of 276.4% from the stock's current price.
View analysts price targets for IPHA
or view top-rated stocks among Wall Street analysts.

How have IPHA shares performed in 2024?

Innate Pharma's stock was trading at $2.80 at the beginning of 2024. Since then, IPHA shares have decreased by 7.5% and is now trading at $2.59.
View the best growth stocks for 2024 here
.

Are investors shorting Innate Pharma?

Innate Pharma saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 76,900 shares, a drop of 13.7% from the March 15th total of 89,100 shares. Based on an average daily volume of 10,000 shares, the short-interest ratio is presently 7.7 days.
View Innate Pharma's Short Interest
.

What is Hervé Brailly's approval rating as Innate Pharma's CEO?

4 employees have rated Innate Pharma Chief Executive Officer Hervé Brailly on Glassdoor.com. Hervé Brailly has an approval rating of 100% among the company's employees. This puts Hervé Brailly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Innate Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include Cidara Therapeutics (cdtx), VBI Vaccines (VBIV), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), INmune Bio (INMB), Pluristem Therapeutics (PSTI) and

When did Innate Pharma IPO?

Innate Pharma (IPHA) raised $80 million in an initial public offering on Thursday, October 17th 2019. The company issued 10,700,000 shares at $7.50 per share. Citigroup, SVB Leerink and Evercore ISI acted as the underwriters for the IPO.

How do I buy shares of Innate Pharma?

Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IPHA) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners